Literature DB >> 8903421

MK386: a potent, selective inhibitor of the human type 1 5alpha-reductase.

K Ellsworth1, B Azzolina, W Baginsky, H Bull, B Chang, G Cimis, S Mitra, J Toney, R K Bakshi, G R Rasmusson, R L Tolman, G S Harris.   

Abstract

Steroid 5alpha-reductase is required for the conversion of testosterone to dihydrotestosterone. Localization of type 1 5alpha-reductase in the sebaceous gland of skin offers the possibility for selective inhibition of this isozyme as a treatment for acne. The goals of these studies are to demonstrate the mechanism of inhibition of MK386 and its selectivity for type 1 5alpha-reductase. The apparent potency of MK386 differed depending on the source of the enzyme (i.e. recombinant vs. native), yet selectivity for type 1 5alpha-reductase was unchanged. Our results indicate that the apparent potency of MK386 is modulated by the membrane concentration of the assay. These results suggest that MK386 has a high affinity for the lipid-rich membrane environment of 5alpha-reductase. MK386 was also found to be a slow binding inhibitor of type 1 5alpha-reductase. However, the cause of this time-dependent inhibition is unrelated to partitioning of the inhibitor into the membrane because similar studies with type 2 5alpha-reductase indicate that MK386 is a reversible, competitive inhibitor. A number of counterscreens were developed to demonstrate that MK386 is a poor inhibitor of other steroid metabolizing enzymes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8903421     DOI: 10.1016/0960-0760(96)00050-7

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  3 in total

1.  The human keratinocyte cell line HaCaT: an in vitro cell culture model for keratinocyte testosterone metabolism.

Authors:  R Altenburger; T Kissel
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

Review 2.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

3.  Allopregnanolone is required for prepulse inhibition deficits induced by D1 dopamine receptor activation.

Authors:  Laura J Mosher; Roberto Cadeddu; Sabrina Yen; Jeffrey L Staudinger; Francesco Traccis; Stephen C Fowler; Jamie L Maguire; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2019-06-14       Impact factor: 4.905

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.